TD Cowen keeps Buy rating on Senseonics with $15 price target
TD Cowen reiterated its Buy rating and $15 target on Senseonics Holdings as the company starts first-in-human testing of its FREEDOM CGM platform.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
TD Cowen reiterated its Buy rating on Senseonics Holdings shares with a $15 price target, TradingView reports. The target implies an upside of 100.5% from the October 26 close of $7.48, according to the report.
The analyst note says Senseonics has begun first-in-human testing of its next-generation FREEDOM continuous glucose monitoring platform, designed to remove the need for an external transmitter. TD Cowen views the preclinical results as supportive of the approach's technical feasibility. Dow Jones Newswires also published the rating update, citing data from Benzinga.
why it matters
For investors, the key point is the planned launches of FREEDOM and GEMINI alongside the existing Eversense 365 line. If these products reach the market on schedule, the company could widen its patient base and its share of the fast-growing CGM segment. Still, this is a single-company rating update with limited relevance for the broader market.
tags
instruments
sources
- TD Cowen reiterates Buy rating on Senseonics Holdings, $15 price target — TradingView, 27 October 2026 at 15:26 UTC
- Senseonics Holdings Price Target Maintained With a $15.00/Share by TD Cowen — Dow Jones Newswires, 27 October 2026 at 15:36 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗